The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...

Approximately 20% of new lung cancer diagnoses occur in nonsmokers in the U.S., according to The Ohio State University ...

If everyone eligible had a lung cancer screening, 62,000 lives would be saved over five years, a new study shows.

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...

A year after she quit smoking, Kim Swart thought the half-million cigarettes she smoked between high school and retirement ...

Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.

Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells ...

When Sydney Barned was first diagnosed with stage 4 lung cancer, she was just 33 years old — a young medical intern focused ...

DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...

ChristianaCare’s Gene Editing Institute says it has found a way to reverse chemotherapy resistance in one of the most common ...